View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 11, 2020updated 07 May 2020 5:32pm

Pfizer: How one of the world’s largest pharma firms is tackling Covid-19

By Jamie Bell

As the sixth most valuable pharmaceutical brand in the world, it is little surprise that US healthcare heavyweight Pfizer has taken numerous steps over the past few months to aid the global response to Covid-19 in any way it can.

After issuing a proverbial call to arms to the rest of the biopharma industry in March, it has also donated $40m towards combatting the virus’ impact and entered into a partnership with German biotech firm BioNTech to develop a novel coronavirus vaccine.

And, with Pfizer revealing the first US clinical trial participants had been dosed with an mRNA-based vaccine earlier this week, we take a closer look at how the American company behind brands such as Xanax, Viagra and ChapStick has responded throughout the pandemic.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena